Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16320900 | 1.00 | PDK1 (0.34) | PDK1MIFHCRTR2CA2 | |
| SCHEMBL7260912 | 1.00 | PDK1 (0.34) | PDK1MIFHCRTR2CA2 | |
| SCHEMBL16365768 | 1.00 | PDK1 (0.34) | PDK1MIFHCRTR2CA2 | |
| SCHEMBL19504070 | 0.91 | ALDH1A1 (0.33) | MIFHCRTR2 | |
| SCHEMBL22349347 | 0.89 | ALDH1A1 (0.47) | MIF | |
| SCHEMBL6872581 | 0.87 | MIF (0.33) | MIFHCRTR2 | |
| SCHEMBL22349327 | 0.84 | ALDH1A1 (0.40) | — | |
| SCHEMBL22043547 | 0.84 | CYP1A2 (0.39) | MIFHCRTR2 | |
| SCHEMBL9453175 | 0.84 | MIF (0.34) | MIFHCRTR2 | |
| SCHEMBL6125270 | 0.84 | MIF (0.34) | MIFHCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116381075-B | GC-MS (gas chromatography-mass spectrometry) -based method for detecting C0 in D5 | 江苏和汇医药科技有限公司 | 2024-03-12 | — | — | CN | claimed |
| CN-116381075-A | GC-MS (gas chromatography-mass spectrometry) -based method for detecting C0 in D5 | 江苏和汇医药科技有限公司 | 2023-07-04 | — | — | CN | claimed |
| CN-115160286-A | Novel preparation process of rosuvastatin calcium intermediate | 南通常佑药业科技有限公司 | 2022-10-11 | — | — | CN | claimed |
| CN-113666905-B | Preparation method of rosuvastatin calcium intermediate | 常州制药厂有限公司 | 2022-07-19 | — | — | CN | claimed |
| CN-113666905-A | Preparation method of rosuvastatin calcium intermediate | 常州制药厂有限公司 | 2021-11-19 | — | — | CN | claimed |
| CN-111675689-A | Chemical synthesis method of rosuvastatin intermediate | 浙江工业大学 | 2020-09-18 | — | — | CN | claimed |
| US-7718812-B2 | Via quaternary phosphonium salt as phase transfer catalyst; oxidation | ASTRAZENECA UK LIMITED (GB) | 2010-05-18 | — | — | US | claimed |
| EP-1461331-B9 | PROCESS FOR THE PREPARATION OF 2-(6-SUBSTITUTED-1,3-DIOXANE-4-YL) ACETIC ACID DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2006-06-28 | — | — | EP | claimed |
| CN-116381075-B | GC-MS (gas chromatography-mass spectrometry) -based method for detecting C0 in D5 | 江苏和汇医药科技有限公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-3445751-B9 | NEW POLYMORPHIC FORM OF CRYSTALLINE ROSUVASTATIN CALCIUM&NOVEL PROCESSES FOR CRYSTALLINE AS WELL AS AMORPHOUS ROSUVASTATIN CALCIUM | MOREPEN LABORATORIES LTD (IN) | 2023-07-26 | — | — | EP | disclosed |
| CN-116381075-A | GC-MS (gas chromatography-mass spectrometry) -based method for detecting C0 in D5 | 江苏和汇医药科技有限公司 | 2023-07-04 | — | — | CN | disclosed |
| EP-3445751-B1 | NEW POLYMORPHIC FORM OF CRYSTALLINE ROSUVASTATIN CALCIUM&NOVEL PROCESSES FOR CRYSTALLINE AS WELL AS AMORPHOUS ROSUVASTATIN CALCIUM | MOREPEN LABORATORIES LTD (IN) | 2023-04-26 | — | — | EP | disclosed |
| CN-115160286-A | Novel preparation process of rosuvastatin calcium intermediate | 南通常佑药业科技有限公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-113666905-B | Preparation method of rosuvastatin calcium intermediate | 常州制药厂有限公司 | 2022-07-19 | — | — | CN | disclosed |
| US-6903225-B2 | Process for producing optically active 2-[6-(hydroxymethyl)-1,3-dioxan-4-yl]acetic acid derivatives | KANEKA CORPORATION (JP) | 2005-06-07 | — | — | US | disclosed |
| EP-1024139-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 2-(6-(HYDROXYMETHYL)-1,3-DIOXAN-4-YL) ACETIC ACID DERIVATIVES | KANEKA CORP (JP) | 2004-05-12 | — | — | EP | disclosed |
| EP-1394157-A2 | Process for the preparation of 3,5-dihydroxy substituted esters as intermediates for producing optically active 2-(6-(hydroxymethyl)-1,3-dioxan-4-yl) acetic acid dervatives | KANEKA CORPORATION (JP) | 2004-03-03 | — | — | EP | disclosed |
| US-20030040634-A1 | Process for producing optically active 2-[6-(hydroxymethyl)-1,3-dioxan-4yl]acetic acid derivatives | KANEKA CORPORATION (JP) | 2003-02-27 | — | — | US | disclosed |
| US-6472544-B1 | REACTING ACETIC ACID DERIVATIVE WITH AN ENOLATE, REDUCING WITH A MICROORGANISM, ACETALIZING IN PRESENCE OF ACID CATALYST THEN ALKALINE SAPONIFICATION; NO SPECIAL EQUIPMENT OR SUPER LOW TEMPERATURE REQUIRED; INEXPENSIVE STARTING MATERIALS | KANEKA CORPORATION (JP) | 2002-10-29 | — | — | US | disclosed |
| EP-1024139-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 2- 6-(HYDROXYMETHYL)-1,3-DIOXAN-4-YL]ACETIC ACID DERIVATIVES | KANEKA CORPORATION (JP) | 2000-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040634-A1 | Process for producing optically active 2-[6-(hydroxymethyl)-1,3-dioxan-4yl]acetic acid derivatives | HAAO, APEH, AADAC | PDK1 1204/4885MIF 3392/4885HCRTR2 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.